Biomedical subjects

A Schmieder

Publications and source records attributed to A Schmieder.

7 recordsLinked to original sources

PubMed1992

Sequential methotrexate and 5-fluorouracil (FU) vs. FU alone in metastatic colorectal cancer. Results of a randomized multicenter trial. The Association of Medical Oncology (AIO) of the German Cancer Society.

Methotrexate (MTX) modulates 5-fluorouracil (FU) in several in vitro and in vivo experimental systems. Results of phase II studies have suggested improved response rates for the sequential application of MTX and FU in colorectal cancer. In a prospective randomized multicenter study we compared sequential MTX (300 mg/m2) and FU (900 mg/m2) using a seven-hour time interval and leucovorin rescue with FU (450 mg/m2/d for five days) in patients with previously untreated metastatic colorectal cancer. Of 172 patients randomized 159 were eligible for survival analysis and 153 for toxicity and response evaluation. Complete or partial response has been seen in 25.3% of patients receiving sequential MTX and FU and in 17.6% of those receiving FU alone (p = 0.11). There have been two long-term survivors, apparently cured by MTX/FU. Overall toxicity was more pronounced with FU alone, but sequential MTX/FU caused four toxic deaths. Median survival and survival rates at one and two years were not significantly different. It is concluded that this schedule of sequential MTX and FU is no more effective than a dose-intensive treatment with FU alone in metastatic colorectal cancer.

Adult↗

PubMed1985

[Primary combined radiotherapy of carcinoma of the uterine cervix. Comparison of 192Ir with radium].

A retrospective study of primary irradiated carcinomas of the uterine cervix was made in order to compare the effect of radium with the effect of a 192Ir afterloading therapy with high dose rate which had been introduced 2 1/2 years before. A group of 31 patients treated with iridium was opposed to a historical control group of 24 patients treated with radium. Both groups were submitted to the same method of simultaneous percutaneous irradiation. All consecutively treated patients exposed to a percutaneous focal dose of greater than 45 Gy were evaluated. The iridium and radium doses applied as well as the values measured in intestine and bladder are presented. The iridium group had the same or a slightly less favorable prognosis (prognostic factors compared: stage, percutaneous dose, histology, age) than the radium group. The remission rates were identical for both therapy methods. Patients treated with iridium have a slightly better curve of recurrence-free interval and survival time, even taking into consideration the shorter observation period. Two out of the patients treated with iridium and four out of those treated with radium presented severe long-term side effects with formation of fistulas (average incidence 12,5 months and 12,7 months after the beginning of therapy, respectively).

Brachytherapy↗

PubMed1984

[Chemotherapy with cisplatin-bleomycin and subsequent radiotherapy in advanced head and neck tumors].

42 patients with advanced stage III and IV squamous cell carcinoma of the head and neck were treated with initial cisplatin and bleomycin chemotherapy and subsequent radiotherapy. 39 were evaluable for results, and 3 for toxicity only. 8 patients suffered from stage III and 31 from stage IV tumors, of these 10 with distant metastases. 5 patients underwent later a rescue operation. 27 were previously untreated (= group A) including 2 cases with localized relapses beyond the margins of surgical and/or radiotherapeutic treatment fields. 12 patients had a recurrence within pretreated areas (= group B). The induction chemotherapy alone showed the following results: In group A 4 (15%) CR, 10 (37%) PR, 7 (26%) MR; in group B 3 (25%) PR, 2 (17%) MR. The subsequent radiotherapy mostly consisted of a 65 Gy tumor dose given in 61/2 weeks. The results after completion of the combined modality therapy were: In group A 44% CR, 28% PR; in group B 10% CR and 30% PR. No patient resistant to the initial chemotherapy responded to the radiotherapy. The median survival time of stage III patients was 20 months but only 7 months in stage IV patients. 4 of all live with NED now between 30+ and 41+ months; 1 patient is alive with relapse. All the others are dead after a survival time of max. 32 months, included the 5 with rescue operation. In general, hematologic and renal toxicities were not severe, but nausea and vomiting were the worst tolerated side effects.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗

PubMed1984

Sequential methotrexate and 5-fluorouracil: improved response rate in metastatic colorectal cancer.

The efficacy of chemotherapy with sequential methotrexate (MTX) and 5-fluorouracil (5-FU) in metastatic colorectal cancer was studied in a multicenter phase II trial using a seven-hour time interval. Forty-two patients were evaluable for response and 16 achieved objective tumor regression (greater than 50%). Median survival of all patients was 12.5 months. The result of this study indicates that MTX and 5-FU are synergistic in human colorectal cancer if given sequentially with a seven-hour time interval. This is supported by a review of the literature that reveals a significantly higher response rate in patients treated with a four-hour or more MTX/5-FU interval as compared to a one-hour interval.

Adult↗

PubMed1984

[Interstitial brachytherapy--initial experiences using 192iridium in short-term therapy].

After a review of the literature dealing with the previous development and the methods of interstitial brachytherapy the high-dose-rate therapy with Iridium-192 is outlined. The proceeding by means of a new afterloading system are depicted. The hitherto acquired indications are treated and discussed in detail. The advantages of this method are emphasized.

Adult↗

PubMed1982

[The problem of multiple breast cancers (author's transl)].

This retrospective study is based on the appearance of bilateral breast cancers -- occurring simultaneously or succeedingly -- in patients our therapeutical radiation section. The examination of 368 patients in the years 1978-1981 gave result of 12 cases (3,2%) showing simultaneous bilateral breast cancer and of 14 cases (3,8%) showing succeeding contralateral breast cancer. Therefore multiple breast cancers are not to be regarded as a limited process but as manifestation in a cancerogenic effective range. This is of prime importance to the diagnosis and therapy of breast cancer.

Adult↗

PubMed1982

[The problem of multiple cancers].

This retrospective study reports on the occurrence of multiple carcinomas among the patients of our Department of Radiotherapy. Examination of 1290 patients during 1978 to 1980 showed in 76 cases (5.8%) simultaneously or successively secondary or tertiary tumours. These multiple tumours were most frequent in the mammary gland, in the female genital organs and in the respiratory system. Women had an incidence which was double of that displayed by men. Diagnosis and therapy of malignant tumours must always consider the possibility of multiplicity of carcinomas, either simultaneously or successively, appearing spontaneously or as a result of iatrogenic influences. This applies in particular to the multicentric and bilateral occurrence of the early types of cancer of the female breast.

Adult↗